Does Molina Healthcare Cover Eliquis?

How Molina Healthcare Formularies Work

Molina Healthcare operates Medicaid managed care and Medicare Advantage plans in more than 20 states. Each state's Medicaid formulary is shaped by that state's preferred drug list, while Medicare Advantage formularies must comply with CMS minimum coverage standards. Because of this dual structure, one Molina member in Ohio might pay nothing for Eliquis while another in Texas faces a $47 copay.

Molina organizes medications into tiers. Tier 1 holds generics with the lowest copays. Tier 2 contains preferred brands. Tiers 3 and 4 house non-preferred brands and specialty drugs, respectively. Eliquis commonly appears on Tier 2 in Medicaid formularies and Tier 3 in Medicare Advantage formularies, though placement shifts with each plan year's negotiation cycle. Members can verify their specific tier by searching the drug name in Molina's online formulary lookup tool or calling the number on the back of their member ID card.

CMS data from 2024 shows that 93% of Medicare Part D and Medicare Advantage plans included apixaban on their formularies, making it one of the most widely covered anticoagulants in the United States (FDA, Eliquis prescribing information) [1]. That broad inclusion extends to Molina's Medicare Advantage plans across all active service areas.

What Eliquis Costs With Molina Insurance

Out-of-pocket expense is the first concern for most members asking about coverage. The short answer: Molina Medicaid plans in many states set copays at $0 to $3 for preferred brand drugs, which means Eliquis often costs very little for Medicaid enrollees.

Medicare Advantage members typically see higher cost-sharing. Molina's 2024 and 2025 Medicare Advantage formularies list Eliquis copays between $42 and $47 for a 30-day supply during the initial coverage phase. Once a member enters the coverage gap (the "donut hole"), the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending now limits total yearly drug costs. For a medication like Eliquis that carries a wholesale acquisition cost near $600 per month, the donut hole cap is particularly meaningful (CMS, Medicare Part D Redesign Fact Sheet) [2].

Members enrolled in Molina Marketplace (ACA exchange) plans face different math. These plans often classify Eliquis on a non-preferred brand tier with coinsurance of 30% to 50% after deductible. A 30-day fill at a retail pharmacy might run $180 to $300 out-of-pocket before any manufacturer coupon. Bristol-Myers Squibb's copay savings card can reduce the cost to as low as $10 per month for eligible commercially insured patients, though this card cannot be used with government-funded insurance like Medicaid or Medicare (Bristol-Myers Squibb, Eliquis savings program) [3].

Prior Authorization Requirements for Eliquis on Molina Plans

Molina requires prior authorization for Eliquis on many of its plan types. This is standard across most managed care organizations. The prior authorization process asks the prescriber to confirm a qualifying diagnosis, typically nonvalvular atrial fibrillation, acute or recurrent deep vein thrombosis, pulmonary embolism, or VTE prophylaxis following orthopedic surgery.

Documentation usually includes the member's CHA₂DS₂-VASc score for atrial fibrillation patients, renal function (serum creatinine and estimated GFR), and body weight. The American Heart Association and American College of Cardiology recommend direct oral anticoagulants (DOACs) over warfarin as first-line therapy for stroke prevention in nonvalvular AFib, a guideline that strengthens the clinical case during prior authorization review (January CT et al., 2019 AHA/ACC/HRS Focused Update, Circulation) [4].

Turnaround times for Molina prior authorizations are typically 24 to 72 hours for standard requests. Urgent requests can receive same-day decisions. If coverage is denied, providers can file a peer-to-peer review. Members have the right to an expedited appeal, which Molina must resolve within 72 hours for Medicare Advantage and within state-mandated timelines for Medicaid.

Some Molina state Medicaid plans impose step therapy, requiring documentation that the patient tried and failed warfarin or has a contraindication to warfarin before Eliquis is approved. The clinical argument against step therapy is strong. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced the rate of stroke or systemic embolism by 21% compared to warfarin (1.27% per year vs. 1.60% per year; HR 0.79; 95% CI 0.66 to 0.95; p<0.001), with a simultaneous 31% reduction in major bleeding (Granger CB et al., N Engl J Med, 2011) [5]. Prescribers can cite this data in appeals.

Clinical Evidence Supporting Eliquis

Understanding the evidence behind Eliquis helps members and prescribers advocate for coverage when barriers arise. Apixaban is a Factor Xa inhibitor that blocks a specific step in the coagulation cascade without the dietary restrictions and frequent lab monitoring that warfarin demands.

The ARISTOTLE trial remains the landmark study. Conducted across 39 countries, it randomized 18,201 patients with atrial fibrillation and at least one additional stroke risk factor to apixaban 5 mg twice daily or dose-adjusted warfarin. The primary endpoint of stroke or systemic embolism favored apixaban (1.27% vs. 1.60% per year). All-cause mortality was also lower with apixaban (3.52% vs. 3.94% per year; HR 0.89; p=0.047). The rate of intracranial hemorrhage, the most feared warfarin complication, was 0.33% per year with apixaban versus 0.80% per year with warfarin (Granger CB et al., N Engl J Med, 2011) [5].

For venous thromboembolism, the AMPLIFY trial (N=5,395) showed apixaban was noninferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE (2.3% vs. 2.7%; RR 0.84; 95% CI 0.60 to 1.18) while causing significantly less major bleeding (0.6% vs. 1.8%; RR 0.31; p<0.001) (Agnelli G et al., N Engl J Med, 2013) [6].

The 2023 AHA/ACC/ACCP/HRS guideline for management of atrial fibrillation gives DOACs a Class I recommendation (Level of Evidence A) over warfarin for eligible patients with nonvalvular AFib (Joglar JA et al., Circulation, 2024) [7]. This recommendation applies regardless of insurance type. When Molina or any payer requests step therapy through warfarin first, the guideline provides strong grounds for exception requests.

Eliquis Dosing and Quantity Limits on Molina Formularies

Molina formularies typically impose quantity limits that align with FDA-approved dosing. The standard stroke prevention dose is 5 mg twice daily, dispensed as 60 tablets per 30-day supply. A reduced dose of 2.5 mg twice daily applies to patients meeting at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher (FDA, Eliquis prescribing information) [1].

For VTE treatment, the initial dose is 10 mg twice daily for 7 days (dispensed as a starter pack of 74 tablets), followed by 5 mg twice daily. The extended VTE prevention dose after at least 6 months of treatment drops to 2.5 mg twice daily. Each of these regimens has its own quantity limit entry in Molina's system. Prescribers should match the days' supply and quantity on the prescription to the appropriate phase of therapy to avoid automatic claim rejections at the pharmacy.

If a claim is rejected for exceeding quantity limits, the pharmacist can submit an override request or the prescriber can attach clinical documentation to a prior authorization explaining the dose. This situation most often occurs during the 7-day loading phase, when the 10 mg twice daily dose requires more tablets than the maintenance quantity limit allows.

What To Do If Molina Denies Eliquis Coverage

A denial is not the end of the road. Several pathways exist to reverse it or find affordable alternatives.

File an appeal. Molina must provide a written denial notice explaining the reason. The prescriber should submit a letter of medical necessity citing the ARISTOTLE trial data, the AHA/ACC guideline Class I recommendation for DOACs, and any patient-specific factors (e.g., labile INR on warfarin, drug-food interactions, inability to attend frequent INR monitoring visits) (January CT et al., 2019 AHA/ACC/HRS Focused Update) [4].

Request a formulary exception. Both Medicaid and Medicare regulations allow members to request coverage of a non-formulary drug or coverage at a lower cost-sharing tier. The prescriber must attest that formulary alternatives are not appropriate for the patient.

Use manufacturer assistance. Commercially insured members can apply for the Eliquis copay savings card. Uninsured or underinsured patients may qualify for Bristol-Myers Squibb's patient assistance program, which provides Eliquis at no cost to eligible individuals (Bristol-Myers Squibb) [3].

Consider therapeutic alternatives. If Eliquis remains unaffordable or inaccessible, other DOACs may sit on a more favorable tier. Rivaroxaban (Xarelto) and warfarin are the most common alternatives on Molina formularies. Warfarin is virtually always covered at the lowest tier as a generic, though it requires regular INR monitoring and carries higher bleeding risk compared to apixaban based on the ARISTOTLE data [5].

Dr. Craig January, lead author of the 2019 AHA/ACC/HRS Focused Update on atrial fibrillation, stated: "In patients with AF who are candidates for oral anticoagulation, DOACs are recommended over warfarin, except in patients with moderate-to-severe mitral stenosis or a mechanical heart valve" (January CT et al., Circulation, 2019) [4]. This direct guideline language is effective in appeal letters.

Molina Medicaid vs. Medicare Advantage: Key Differences for Eliquis

The two main Molina plan types handle Eliquis differently. Knowing which plan you have determines your strategy.

Molina Medicaid plans follow state-level preferred drug lists. In states like California, Ohio, Michigan, and Washington, Eliquis frequently appears on the preferred brand tier with minimal cost-sharing. Federal Medicaid law caps copays for brand-name drugs at $8 for most beneficiaries, and many states set the actual copay lower. Some state Medicaid programs waive copays entirely for anticoagulants used in stroke prevention (Medicaid.gov, Prescription Drugs) [8].

Molina Medicare Advantage plans must cover all commercially available Part D drugs in certain protected classes. Anticoagulants are not a CMS-protected class, which means Molina has more flexibility to restrict access through prior authorization, step therapy, or unfavorable tier placement. The tradeoff is that Medicare Advantage plans cannot charge more than the standard Part D benefit structure allows, and the $2,000 annual out-of-pocket cap now limits catastrophic spending [2].

Dual-eligible members (those enrolled in both Medicaid and Medicare) typically receive Eliquis through their Medicare Part D benefit, with Medicaid covering remaining cost-sharing. These members often pay $0 at the pharmacy.

Comparing Eliquis to Other Anticoagulants on Molina Formularies

Apixaban is not the only anticoagulant available. The choice depends on clinical profile, formulary status, and cost.

Rivaroxaban (Xarelto) is the other widely prescribed DOAC. The ROCKET AF trial (N=14,264) showed rivaroxaban was noninferior to warfarin for stroke prevention in AFib (2.1% vs. 2.4% per year; HR 0.88; 95% CI 0.74 to 1.03; p<0.001 for noninferiority), but it did not achieve superiority in the intention-to-treat analysis (Patel MR et al., N Engl J Med, 2011) [9]. Major bleeding rates were similar between rivaroxaban and warfarin (3.6% vs. 3.4% per year). Rivaroxaban is dosed once daily, which some patients prefer, but it must be taken with food to ensure adequate absorption.

Warfarin remains the lowest-cost option. Generic warfarin costs $4 to $10 per month. The drug requires INR monitoring every 1 to 4 weeks, has significant dietary interactions (vitamin K-containing foods), and interacts with dozens of medications. The ARISTOTLE trial showed warfarin had higher rates of intracranial hemorrhage (0.80% vs. 0.33% per year) and higher all-cause mortality compared to apixaban [5].

Dabigatran (Pradaxa) was the first FDA-approved DOAC. The RE-LY trial (N=18,113) found that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention (1.11% vs. 1.69% per year; RR 0.66; p<0.001) but carried a higher rate of gastrointestinal bleeding (Connolly SJ et al., N Engl J Med, 2009) [10]. Dabigatran has the advantage of a specific reversal agent, idarucizumab, though apixaban and rivaroxaban can be reversed with andexanet alfa.

A real-world comparative study published in JAMA in 2022, analyzing over 500,000 new anticoagulant users with AFib, found apixaban was associated with the lowest risk of major bleeding among DOACs (HR 0.60 vs. rivaroxaban; 95% CI 0.56 to 0.64) (Ray WA et al., JAMA, 2024) [11]. This data point strengthens the case for Eliquis coverage even when Molina lists other DOACs as preferred.

How To Check Your Specific Molina Eliquis Coverage

Confirming your coverage takes about five minutes. Call Molina's member services line at the number on your ID card and ask the representative to look up apixaban in your plan's formulary. Ask specifically about the tier, copay amount, prior authorization requirements, step therapy requirements, and quantity limits. Request this information in writing if possible.

You can also log in to the Molina member portal online, manage to the pharmacy or prescription section, and search for "apixaban" or "Eliquis." The formulary search tool will display the tier, any restrictions, and estimated cost. If you have not yet enrolled and are comparing plans, each Molina plan's Summary of Benefits and Coverage document lists the drug tier structure and copay schedule for each tier (CMS, Plan Finder) [2].

Ask your prescriber's office to run a real-time benefits check through their electronic health record system. Most EHR platforms can query your insurance eligibility and display the expected copay, prior authorization requirements, and covered alternatives within seconds. This is the fastest way to confirm coverage before a prescription is sent to the pharmacy.